NVP-BAW2881 NEW
| Price | $30 | $43 | $68 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: NVP-BAW2881 | CAS No.: 861875-60-7 |
| Purity: 99.97% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | NVP-BAW2881 |
| Description | NVP-BAW2881 (BAW2881) is a potent and selective VEGFR (vascular endothelial growth factor receptor tyrosine kinase) inhibitor with efficacy in inhibiting chronic and acute skin inflammation. |
| Cell Research | HUVECs or LECs (1.2×103) were seeded into fibronectin-coated 96-well plates. After 24 hours, the cells were transferred into LEC medium containing 2% fetal bovine serum and incubated for an additional 24 hours. Cells(eight wells/condition) were incubated with medium alone(control), 20 ng/ml VEGF-A, or a combination of 20 ng/ml VEGF-A and 1 nmol/L to 1 mol/L NVP-BAW2881. Proliferation was also assayed in LECs incubated with 500 ng/ml VEGF-C. The dimethyl sulfoxide concentration was adjusted to 0.1% in all wells. After 72 hours, cells were incubated with 5-methylumbelliferylheptanoate for subsequent fluorescent quantification of viable cells, using a SpectraMax Gemini electron microscope. (Only for Reference) |
| In vitro | In vitro experiments demonstrated that NVP-BAW2881 was able to inhibit the proliferation, migration, and tubulogenesis of human lymphatic endothelial cells and umbilical vein endothelial cells. |
| In vivo | In vitro experiments demonstrated that NVP-BAW2881 was able to inhibit the proliferation, migration, and tubulogenesis of human lymphatic endothelial cells and umbilical vein endothelial cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 78 mg/mL (183.8 mM) Ethanol : 16 mg/mL (37.7 mM) |
| Keywords | NVP-BAW-2881 | NVPBAW2881 | inhibit | NVP-BAW2881 | NVP BAW2881 | Vascular endothelial growth factor receptor | VEGFR | Inhibitor | BAW 2881 | NVP-BAW 2881 | BAW-2881 |
| Inhibitors Related | Ribociclib | Nintedanib | Regorafenib monohydrate | Sorafenib | Regorafenib | Dabrafenib | Sorafenib tosylate | PLX-4720 | Lenvatinib mesylate | Imatinib | Pazopanib | Axitinib |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Angiogenesis related Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1MG |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-10-29 | |
| $747.00/50mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $1.00/1g |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-20 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY